A Phase 2 Proof-of-Concept clinical trial to quantify myocardial manganese uptake rate by cardiovascular magnetic resonance imaging following mangafodipir trisodium administration in healthy volunteers and heart failure patients with preserved ejection fraction caused by hypertrophic cardiomyopathy or cardiac amyloidosis. - MNC001
Latest Information Update: 12 Jan 2026
At a glance
- Drugs Mangafodipir (Primary) ; Gadoterate-meglumine
- Indications Heart failure
- Focus Pharmacokinetics; Proof of concept
Most Recent Events
- 08 Jan 2026 Status changed from active, no longer recruiting to completed.
- 11 Sep 2025 New trial record